The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial

Autor:	Geoffrey T. Jao, Joel Eggebeen, Peter H. Brubaker, Kathryn P. Stewart, Timothy M. Morgan, Bharathi Upadhya, Dalane W. Kitzman
Rok vydání:	2018
Předmět:	Male medicine.medical_specialty Blood Pressure 030204 cardiovascular system & hematology Placebo Article Double blind 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Fumarates Older patients Internal medicine Humans Medicine 030212 general & internal medicine Antihypertensive Agents Aged Randomized Controlled Trials as Topic Heart Failure Exercise Tolerance Ejection fraction business.industry Stroke Volume Aliskiren medicine.disease Amides Blood pressure chemistry Heart failure Cardiology Female Cardiology and Cardiovascular Medicine business Anaerobic exercise
Zdroj:	Am Heart J
ISSN:	0002-8703
DOI:	10.1016/j.ahj.2018.03.019
Popis:	In older patients (70 ± 7 years) with chronic well-compensated heart failure with preserved ejection and controlled blood pressure, 6 months treatment with aliskiren (direct renin inhibitor) showed non-significant trends for modest improvements in peak exercise oxygen consumption (14.9 ± 0.2 mL kg-1 min-1 versus 14.4 ± 0.2 mL kg-1 min-1; P = .10, trend) and ventilatory anaerobic threshold (888 ± 19 mL/min versus 841 ± 18 mL/min; P = .08).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b8480199b5660a0096c163948f0b9fb https://doi.org/10.1016/j.ahj.2018.03.019 Zobrazit plný text záznamu Full Text from ScienceDirect